Skip to main content
Back
Watch Compare

CNBX Pharmaceuticals Inc.

Data quality: 100%
CNBX
OTC Manufacturing Chemicals
$0.00
$0.00 (0.00%)
Mkt Cap: 87,076.0
Price
$0.00
Mkt Cap
87,076.0
Day Range
$0.00 — $0.00
52-Week Range
$0.00 — $0.01
Volume
9
Open $0.00
50D / 200D Avg
$0.00
0.00% above
50D / 200D Avg
$0.00
75.00% below

Quick Summary

Key Takeaways

Negative free cash flow of -179,636.0

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)-100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio0.00
Interest Coverage-3.60

Valuation

PE (TTM)
-0.22
Above sector avg (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.2 -1.5
P/B — 1.6
ROE % — -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -100.00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -393,343.0
ROE N/A ROA -2641.92%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -179,636.0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.00
Interest Coverage -3.60 Asset Turnover 0.00
Working Capital -2.57 M Tangible Book Value -2.57 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.22 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -206.30%
Market Cap 87,076.0 Enterprise Value 79,373.0
Per Share
EPS (Diluted TTM) 0.00 Revenue / Share 0.00
FCF / Share 0.00 OCF / Share 0.00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 45.67%
SBC-Adj. FCF -214,611 Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 130,074.0 410,165.0 — 0.0
Net Income -313,976.0 -695,198.0 -3.71 M -3.72 M -3.19 M
EPS (Diluted) 0.00 -0.02 -0.42 -3.59 —
Gross Profit — — — — —
Operating Income -271,691.0 -583,139.0 -931,380.0 -2.95 M -2.60 M
EBITDA — — — — —
R&D Expenses 0.0 194,788.0 431,565.0 1.18 M 1.77 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 39,819.0 — — — —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 18,437.0 31,383.0 499,039.0 811,166.0 3.08 M
Total Liabilities — — — — —
Shareholders' Equity -2.50 M -2.48 M -2.02 M -1.63 M 1.81 M
Total Debt — — — — —
Cash & Equivalents 15,111.0 26,416.0 129,696.0 117,515.0 1.39 M
Current Assets 18,437.0 31,383.0 224,308.0 198,287.0 1.59 M
Current Liabilities 2.51 M 2.51 M 2.52 M 2.44 M 1.27 M